Open an account

Absci

ABSI · NASDAQ

$9.07+$0.53 (+6.21%)TodayMarket closed ·
Prev close $8.54

About ABSI

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 140 full-time employees. The company went IPO on 2021-07-22. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. The company has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.

Employees
140
Headquarters
Vancouver Washington, Washington
Listed
Jul 22, 2021
Sector
Health Care
Industry
Biotechnology
Website
absci.com

ABSI key statistics

Market cap
1.56B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
4.26M
Volume
2.83M
Open price
$8.50
High today
$9.10
Low today
$8.22
52 Week high
$12.06
52 Week low
$2.24

Absci (ABSI) at a glance

Absci (ABSI) last traded at $9.07, with a market cap of 1.56B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $8.22 and $9.10. The current price is 10.3% above the day's low and 0.3% below its high.

Volume so far is 2.83M shares, below the average of 4.26M shares a day.

Over the past year Absci has ranged from $2.24 to $12.06, and now sits 70% of the way up that range.

Absci met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.21 per share against an estimate of -$0.2053.

The average analyst price target is $14.73, 62.4% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 9 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 12 analystsAvg $14.73
Low
$10.10
Now
$9.07
High
$17.85

ABSI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 9.7% on average.

  1. Q3 FY24: reported -$0.24 per share against an estimate of -$0.2122
  2. Q4 FY24: reported -$0.25 per share against an estimate of -$0.2433
  3. Q1 FY25: reported -$0.21 per share against an estimate of -$0.2346
  4. Q2 FY25: reported -$0.24 per share against an estimate of -$0.2162
  5. Q3 FY25: reported -$0.20 per share against an estimate of -$0.2159
  6. Q4 FY25: reported -$0.20 per share against an estimate of -$0.1982
  7. Q1 FY26: reported -$0.19 per share against an estimate of -$0.2142
  8. Q2 FY26: reported -$0.21 per share against an estimate of -$0.2053

ABSI news

  • Press releaseGlobe Newswire

    AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • Avi Kapoor

    Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday

  • Vandana Singh

    Eli Lilly Utilizes Weight-Loss Drug Profits To Fund Women's Health Initiatives: Report

  • Press releasePRNewswire

    AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030

  • Press releaseGlobe Newswire

    Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releasePRNewswire

    A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed

Similar companies

Companies in the same industry as Absci

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.